CAP-100
Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Phase 1Active
Key Facts
Indication
Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Phase
Phase 1
Status
Active
Company
About Catapult Therapeutics
Catapult Therapeutics is a Dutch-Spanish biotech advancing CAP-100, a first-in-class anti-CCR7 antibody for hematological cancers. Its lead program is in Phase 1 for relapsed/refractory CLL/SLL, with a mechanism that blocks tumor cell migration to lymph nodes and induces cell killing. The company leverages proprietary antibody generation technology from Pepscan and is led by a cross-border team of experienced managers and scientists.
View full company profile